natgillin/translations-raw huggingface dataset:
For storage conditions after first opening of the medicinal product, see section 6.3. 
Za shranjevanje zdravila po prvem odprtju vsebnika glejte poglavje 6.3.
No special requirements. 
Ni posebnih zahtev za odstranjevanje.
The clinical significance of reduced abacavir and zidovudine concentrations is unknown. 
Klinični pomen zmanjšane koncentracije abakavirja in zidovudina ni znan.
Sedatives/hypnotics 
Sedativi/ hipnotiki
Lopinavir: ↔ (relative to historical comparison) 
lopinavir: ↔ (v primerjavi z retrospektivno primerjavo)
There are limited pharmacokinetic data in children below 2 years of age. 
Farmakokinetični podatki pri otrocih do 2. leta starosti so omejeni.
− Always keep enough lopinavir/ritonavir on hand so you don't run out. 
- Vedno imejte pri roki dovolj lopinavirja/ritonavirja, da vam ga ne bo zmanjkalo.
Virologic Response of Study Subjects at Week 48 and Week 96 Week 48 
Virološk i odziv preiskovancev v študiji po 48 in 96 tednih 48. teden
The increased digoxin level may lessen over time as Pgp induction develops. 
Povečana koncentracija digoksina se sčasoma lahko zmanjša, ko se razvije indukcija Pgp.
* n = 18 for Cmax ** n = 16 for Cpredose 
* n = 18 za Cmax
Studies in rats revealed that lopinavir is excreted in the milk. 
Dojenje Študije pri podganah so pokazale, da se lopinavir izloča v mleku.
Pharmacotherapeutic group: antivirals for systemic use, antivirals for treatment of HIV infections, combinations, ATC code: J05AR10 
Farmakoterapevtska skupina: protivirusne učinkovine za sistemsko uporabo, protivirusne učinkovine za zdravljenje okužb s HIV, kombinacije, oznaka ATC: J05AR10
The dose increase did not result in a significant increase in the plasma lopinavir concentration. 
Povečanje odmerka ni povzročilo pomembnega povečanja plazemske koncentracije lopinavirja.
− It is recommended that HIV-infected women do not breast-feed their infants because there is a possibility that the baby can be infected with HIV through your breast milk. 
- Priporočeno je, da z virusom HIV okužene ženske ne dojijo, ker se otrok lahko z materinim mlekom okuži z virusom HIV.
Treatment of overdose with lopinavir/ritonavir is to consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. 
Zdravljenje prevelikega odmerjanja lopinavirja/ritonavirja mora obsegati splošne podporne ukrepe, vključno z nadziranjem vitalnih znakov in opazovanjem bolnikovega kliničnega stanja.
Do not drive a car or operate machinery if you experience any side effects (e.g. nausea) that impact your ability to do so safely. 
Ne vozite in ne upravljajte s stroji, če se vam pojavi katerikoli neželeni učinek (npr. siljenje na bruhanje), ki bi vplival na vaše varno ravnanje.
Since these patients had not previously been exposed to either lopinavir/ritonavir or efavirenz, part of the response may be attributed to the antiviral activity of efavirenz, particularly in patients harbouring highly lopinavir resistant virus. 
Ker ti bolniki predhodno niso bili izpostavljeni niti lopinavirju/ritonavirju niti efavirenzu, je del odziva mogoče pripisati protivirusni dejavnosti efavirenza, zlasti pri bolnikih, ki so imeli proti lopinavirju zelo odporen virus.
This may result in lowered plasma concentrations and potential decrease of efficacy of co-administered medicinal products. 
To lahko zmanjša plazemske koncentracije in potencialno zmanjša učinkovitost sočasno uporabljenih zdravil.
Postpartum n = 17** 
Po porodu n = 17**
Mylan SAS 117 Allee des Parcs 69800 Saint-Priest France 
117 Allee des Parcs 69 800 Saint Priest Francija
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. 
- Preobčutljivost na zdravilni učinkovini ali katerokoli pomožno snov, navedeno v poglavju 6.1.
When you travel or need to stay in the hospital make sure you will have enough lopinavir/ritonavir to last until you can get a new supply. 
Če greste na potovanje ali v bolnišnico, imejte s seboj vedno toliko lopinavirja/ritonavirja, da vam bo zadostovalo, dokler ne dobite nove zaloge.
(combinations of mechanisms including CYP3A inhibition) 
(kombinacije mehanizmov, vključno z inhibicijo CYP3A)
Diarrhoea, nausea and vomiting may occur at the beginning of the treatment while hypertriglyceridaemia and hypercholesterolemia may occur later. 
Driska, navzea in bruhanje se lahko pojavijo v začetku zdravljenja, medtem ko se hipertrigliceridemija in hiperholesterolemija lahko pojavita kasneje.
Lopinavir/ritonavir may cause changes in your heart rhythm and the electrical activity of your heart. 
Lopinavir/ritonavir lahko povzroči spremembe srčnega ritma in električne aktivnosti srca.
Further stratification within each group was 1:1 (tablet versus. 
Dodatna stratifikacija znotraj posamezne skupine je bila narejena v razmerju 1:1 (tablete v primerjavi z mehkimi kapsulami).
Treatment emergent adverse events led to premature study discontinuation for 7% of subjects from Phase II-IV studies. 
Hudi neželeni učinki, ki so se pojavili med zdravljenjem, so vodili do predčasne prekinitve terapije pri 7% bolnikov v študijah faze II doIV.
Fluvastatin or Pravastatin Fluvastatin, Pravastatin: No clinical relevant interaction expected. 
fluvastatin ali pravastatin fluvastatin, pravastatin: klinično pomembnih medsebojnih delovanj ni pričakovati.
− For children, your doctor will decide the right dose (number of tablets) based on the child's height and weight. 
- Pravi odmerek (število tablet) za otroka bo zdravnik določil na osnovi otrokove višine in telesne mase.
Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. 
Lopinavir je zaviralec proteaz HIV-1 in HIV-2.
In post-marketing surveillance through the Antiretroviral Pregnancy Registry, established since January 1989, an increased risk of birth defects exposures with lopinavir/ritonavir has not been reported among over 1000 women exposed during the first trimester. 
V nadzoru v obdobju trženja s pomočjo Protiretrovirusnega nosečnostnega registra, ki je vzpostavljen od januarja 1989, niso poročali o povečanem tveganju prirojenih napak med 1000 ženskami, ki so bile izpostavljene v prvem trimesečju.
The pharmacokinetic properties of lopinavir co-administered with ritonavir have been evaluated in healthy adult volunteers and in HIV-infected patients; no substantial differences were observed between the two groups. 
Farmakokinetične lastnosti lopinavirja, uporabljenega hkrati z ritonavirjem, so ocenili pri zdravih odraslih prostovoljcih in pri bolnikih, okuženih z virusom HIV; med skupinama niso opazili bistvenih razlik.
Do not take Lopinavir/Ritonavir Mylan if: - you are allergic to lopinavir, ritonavir or any of the other ingredients of this medicine (listed in section 6); - you have severe liver problems. 
Ne jemljite zdravila Lopinavir/ritonavir Mylan, če: - ste alergični na lopinavir, ritonavir ali katerokoli drugo sestavino tega zdravila (navedeno v poglavju 6); - imate hude težave z jetri.
− The usual adult dose is 400 mg/100 mg twice a day i.e. every 12 hours, in combination with other antiHIV medicines. 
- Običajni odmerek za odrasle je 400 mg/100 mg dvakrat na dan, to je vsakih 12 ur, v kombinaciji z drugimi zdravili proti okužbam z virusom HIV.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please inform your doctor or pharmacist. 
Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite zdravnika ali farmacevta.
The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia. 
Kombinacija lahko poveča tveganje za srčno-žilne neželene učinke, povezane s salmeterolom, vključno s podaljšanjem QT, palpitacijami in sinusno tahikardijo.
HIV-1 isolates with reduced susceptibility to lopinavir have been selected in vitro. 
Izolati virusa HIV-1 z zmanjšano občutljivostjo za lopinavir so bili izbrani in vitro.
All interaction studies, when otherwise not stated, were performed using lopinavir/ritonavir capsules, which gives an approximately 20% lower exposure of lopinavir than the 200/50 mg tablets. 
Vse študije interakcij, če ni drugače navedeno, so bile izvedene z uporabo zdravila lopinavir/ritonavir kapsule, kar pomeni za približno 20 % nižjo izpostavljenost lopinavirju kot pri 200 mg/50 mg tabletah.
Lopinavir/ritonavir has not specifically been tested for its possible effects on the ability to drive a car or operate machines. 
Lopinavirja/ritonavirja niso posebej preizkušali glede možnih učinkov na sposobnost za upravljanje vozil ali delo s stroji.
− Breast-feeding mothers should not take lopinavir/ritonavir unless specifically directed by the doctor. 
- Doječe matere ne smejo jemati lopinavirja/ritonavirja, razen če jim tega posebej ne naroči zdravnik.
No pattern of birth defects suggestive of a common etiology was seen. 
V skupni etilogiji niso opazili vzorca prirojenih napak.
A limited increase in total lopinavir concentrations of approximately 30% has been observed which is not expected to be of clinical relevance (see section 4.2). 
Opazili so omejeno povečanje koncentracij lopinavirja za približno 30 %, kar ni pričakovati, da bi bilo klinično pomembno (glejte poglavje 4.2).
− Tell your doctor immediately if you are planning to have a baby, you are pregnant, think you may be pregnant or if you are breast-feeding. 
- Zdravniku takoj povejte, če nameravate zanositi, če ste ali če mislite, da bi lahko bili noseči, ali če dojite.
Table 6 Mean (%CV) Steady-State Pharmacokinetic Parameters of Lopinavir in HIV-Infected Pregnant Women 
Srednji (% CV) farmakokinetični parametri v stanju ravnovesja za lopinavir pri nosečnicah, okuženih z virusom HIV
Mechanism of action 
Mehanizem medsebojnega delovanja
Children less than 2 years of age 
Otroci do 2. leta starosti
Lopinavir/ritonavir does not inhibit CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 or CYP1A2 at clinically relevant concentrations (see section 4.3). 
Lopinavir/ritonavir v klinično pomembnih koncentracijah ne zavira CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 ali CYP1A2 (glejte poglavje 4.3).
Outcomes at Week 48: Study M98-863 Lopinavir/ritonavir (N=326) 
Rezultati v 48.tednu: Študija M98-863 lopinavir/ritonavir (N=326)
− medicines used to treat pulmonary arterial hypertension (high blood pressure in the pulmonary artery) 
- zdravila za zdravljenje pljučne arterijske hipertenzije (visokega krvnega tlaka v pljučni arteriji)
The use of a once daily dosing should be limited to those adult patients having only very few protease inhibitor (PI) associated mutations (i.e. less than 3 PI mutations in line with clinical trial results, see section 5.1 for the full description of the population) and should take into account the risk of a lesser sustainability of the virologic suppression (see section 5.1) and higher risk of diarrhoea (see section 4.8) compared to the recommended standard twice daily dosing. 
Uporabo enkrat na dan je treba omejiti na odrasle, ki imajo le zelo malo mutacij, povezanih z zaviralci proteaz (manj kot 3 takšne mutacije v skladu z rezultati klinične študije; za celoten opis populacije glejte poglavje 5.1), in upoštevati je treba tveganje manjše stalnosti virološke supresije (glejte poglavje 5.1) in večje tveganje driske (glejte poglavje 4.8) v primerjavi s priporočeno standardno uporabo dvakrat na dan.
Other forms of this medicine may be more suitable for children; ask your doctor or pharmacist. 
Za otroke so morda primernejše druge farmacevtske oblike tega zdravila; posvetujte se z zdravnikom ali framacevtom.
Subsequently, all patients were continued on the 300/75 mg per m2 dose. 
Potem so vsi bolniki nadaljevali z odmerkom 300 mg/75 mg na m2.
Within this panel, the following mutations in HIV protease were associated with reduced in vitro susceptibility to lopinavir: L10F/I/R/V, K20M/R, L24I, M46I/L, F53L, I54L/T/V, L63P, A71I/L/T/V, V82A/F/T, I84V and L90M. 
V tem okviru so bile z manjšo občutljivostjo za lopinavir in vitro povezane naslednje mutacije proteaze HIV: L10F/I/R/V, K20M/R, L24I, M46I/L, F53L, I54L/T/V, L63P, A71I/L/T/V, V82A/F/T, I84V in L90M.
Paediatric populations 
Pediatrična populacija
The safety of lopinavir/ritonavir has been investigated in over 2600 patients in Phase II-IV clinical trials, of which over 700 have received a dose of 800/200 mg (6 capsules or 4 tablets) once daily. 
Varnost lopinavirja/ritonavirja so raziskali pri več kot 2600 bolnikih v kliničnih preskušanjih faze II do IV, v katerih jih je preko 700 prejemalo odmerek 800 mg/200 mg (6 kapsul ali 4 tablete) enkrat dnevno.
Voriconazole: Concentrations may be decreased. 
vorikonazol vorikonazol: koncentracija se lahko zmanjša.
See section 4.4 and section 4.5 for co-administration of sildenafil in patients with erectile dysfunction. 
Glejte poglavje 4.4 in poglavje 4.5 za sočasno uporabo sildenafila pribolnikih zerektilno disfunkcijo.
For patients who have completed the ramp-up phase and are on a steady daily dose of venetoclax, reduce the venetoclax dose by at least 75% when used with strong CYP3A inhibitors (refer to the venetoclax SmPC for dosing instructions). 
Za bolnike, ki so zaključili fazo povečevanja odmerka in prejemajo stalen dnevni odmerek venetoklaksa, zmanjšajte dnevni odmerek venetoklaksa za najmanj 75 %, kadar je ta uporabljen z močnimi zaviralci CYP3A (glejte povzetek glavnih značilnosti zdravila za venetoklaks).
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jiroveci pneumonia. 
Ustrezni primeri so citomegalovirusni retinitis, generalizirane in/ali žariščne okužbe z mikobakterijami in s Pneumocystis jiroveci povzročena pljučnica.
In some patients with advanced HIV infection and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. 
- Pri bolnikih z napredovalo okužbo z virusom HIV in z zgodovino opurtunistične infekcije se lahko znaki in simptomi vnetja prejšnje infekcije pojavijo kmalu po uvedbi zdravljenja zoper okužbo z virusom HIV.
Lopinavir/ritonavir does this by slowing down the spread of the infection in your body. 
Lopinavir/ritonavir to doseže tako, da upočasni širjenje okužbe v telesu.
Sustained virological response to lopinavir/ritonavir (in combination with nucleoside/nucleotide reverse transcriptase inhibitors) has been also observed in a small Phase II study (M97-720) through 360 weeks of treatment. 
Dolgotrajni virološki odziv na lopinavirj/ritonavir (v kombinaciji z nukleozidnimi/nukleotidnimi zaviralci reverzne transkriptaze) so ugotovili tudi v majhni študiji faze II (M97-720) med 360 tedni zdravljenja.
Co-administration with other HIV protease inhibitors (PIs) According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended. 
Sočasna uporaba z drugimi zaviralci proteaz HIV (PI) Glede na trenutne terapevtske smernice dvotirno zdravljenje z zaviralci proteaz praviloma ni priporočljivo.
For infants and young children unable to swallow tablets, more suitable formulations containing lopinavir/ritonavir should be checked for their availability. 
Za dojenčke in majhne otroke, ki ne morejo pogoltniti tablet, je treba preveriti razpoložljivost primernejše farmacevtske oblike, ki vsebuje lopinavir/ritonavir.
As a general rule, it is recommended that mothers infected by HIV do not breastfeed their babies under any circumstances in order to avoid transmission of HIV. 
V splošnem se priporoča, da doječe matere, okužene z virusom HIV, nikakor ne smejo dojiti, da ne pride do prenosa virusa HIV na otroka.
Concomitant Therapy: Efavirenz or nevirapine 
Sočasno zdravljenje: efavirenz ali nevirapin
Strong CYP3A4 inhibitors such as protease inhibitors may increase bedaquiline exposure which could potentially increase the risk of bedaquiline related adverse reactions. 
Močni zaviralci CYP3A4 kot so zaviralci proteaz lahko povečajo izpostavljenost bedakilinu, kar bi potencialno lahko povečalo tveganje za neželene učinke povezane z bedakilinom.
The safety and efficacy of lopinavir/ritonavir has not been established in patients with significant underlying liver disorders. 
Varnost in učinkovitost lopinavirja/ritonavirja nista ugotovljeni pri bolnikih s pomembnimi osnovnimi boleznimi jeter.
Patients with pre-existing liver dysfunction including chronic hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice. 
Pri bolnikih z predobstoječo disfunkcijo jeter, vključno s kroničnim hepatitisom, se med kombiniranim protiretrovirusnim zdravljenjem pogosteje pojavljajo nepravilnosti v delovanju jeter, zato jih je treba nadzirati v skladu s standardno prakso.
No subject experienced an increase in QTcF of ≥ 60 ms from baseline or a QTcF interval exceeding the potentially clinically relevant threshold of 500 ms. 
Nobenemu preiskovancu se QTcF ni podaljšal za ≥ 60 ms v primerjavi z izhodiščem, dolžina intervala QTcF pa ni pri nobenem presegla potencialno klinično pomembnega praga 500 ms.
You should tell your doctor promptly about these or any other symptoms. 
Zdravnika takoj obvestite o neželenih učinkih ali katerihkoli drugih simptomih.
Antipsychotics/ Neuroleptics 
Antipsihotiki/ nevroleptiki lurasidon
Further dosage reduction of rifabutin to 150 mg twice weekly on set days is recommended for patients in whom the 150 mg dose 3 times per week is not tolerated. 
Nadaljnje zmanjševanje odmerka rifabutina na 150 mg 2-krat na teden ob določenih dnevih je priporočljivo pribolnikih, ki ne prenašajo odmerka 150 mg 3-krat na teden.
− If you are currently using an oral contraceptive or using a patch contraceptive to prevent pregnancy, you should use an additional or different type of contraception (e.g. condom) as lopinavir/ritonavir may reduce the effectiveness of oral and patch contraceptives. 
- Če za preprečevanje nosečnosti jemljete peroralne kontraceptive ali kontraceptive v obliki obliža, morate uporabiti dodatno ali drugačno kontracepcijsko zaščito (npr. kondom), kajti lopinavir/ritonavir lahko zmanjša učinkovitost peroralnih kontraceptivov ali kontraceptivov v obliki obliža.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free'. 
To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na tableto, kar v bistvu pomeni ''brez natrija''.
− Lopinavir/ritonavir should always be taken every day to help control your HIV infection, no matter how much better you feel. 
- Da bo lopinavir/ritonavir pomagal obvladovati okužbo z virusom HIV, ga morate vzeti vsak dan, ne glede na to, koliko bolje se počutite.
If you are taking lopinavir/ritonavir once a day 
Če jemljete lopinavir/ritonavir enkrat na dan
Increased plasma concentrations of quetiapine which may lead to coma. 
Povečana plazemska koncentracija kvetiapina, ki lahko vodi v komo.
− If you realise you have taken more lopinavir/ritonavir than you were supposed to, contact your doctor right away. 
- Če ugotovite, da ste vzeli več lopinavirja/ritonavirja, kot bi bilo treba, se takoj posvetujte z zdravnikom.
− Muscle pain, tenderness or weakness, particularly in combination with these medicines. 
- Bolečine, občutljivost ali šibkost mišic, zlasti v kombinaciji s protiretrovirusnimi zdravili.
− Lopinavir/ritonavir does not reduce the risk of passing HIV to others. 
- Lopinavir/ritonavir ne zmanjša tveganja za prenos okužbe z virusom HIV na druge.
Unless otherwise stated, studies detailed below have been performed with the recommended dosage of lopinavir/ritonavir (i.e. 400/100 mg twice daily). 
Če ni navedeno drugače, so bile spodaj omenjene študije opravljene s priporočenim odmerjanjem lopinavirja/ritonavirja (tj. 400 mg/100 mg dvakrat na dan).
− Do not stop or change the daily dose of lopinavir/ritonavir without first consulting with your doctor. 
- Dnevnega odmerka lopinavirja/ritonavirja ne opuščajte in ne spreminjajte, ne da bi se prej posvetovali z zdravnikom.
The adequate dosing may be achieved with the two available strengths of lopinavir/ritonavir tablets: 100/25 mg and 200/50 mg.* 
Ustrezen odmerek lahko dosežemo z uporabo dveh razpoložljivih jakosti tablet lopinavirja/ritonavirja: 100 mg/25 mg in 200 mg/50 mg.*
The enrolled population was moderately PI-experienced with more than half of patients having never received prior PI and around 80% of patients presenting a viral strain with less than 3 PI mutations. 
Vključena populacija je bila zmerno izkušena z zaviralci proteaz: več kot polovica bolnikov ni še nikoli prej dobivalo zaviralce proteaz in približno 80 % bolnikov je imelo virusni sev z manj kot tremi mutacijami, povezanimi z zaviralci proteaz.
Based on the current data available, lopinavir/ritonavir should not be administered once daily in paediatric patients (see section 5.1). 
Na podlagi omejenih dosedanjih podatkov, ki so na razpolago, se lopinavirja/ritonavija ne sme odmerjati enkrat na dan pri pediatričnih bolnikih (glejte poglavje 5.1).
(see section 4.5); - riociguat is not recommended (see section 4.5); - vorapaxar is not recommended (see section 4.5); - fusidic acid in osteo-articular infections is not recommended (see section 4.5); - salmeterol is not recommended (see section 4.5); - rivaroxaban is not recommended (see section 4.5). 
Kombinacija lopinavirja/ritonavirja s/z: - tadalafilom, uporabljenim za zdravljenje pljučne arterijske hipertenzije, ni priporočljiva (glejte poglavje 4.5); - riociguatom ni priporočljiva (glejte poglavje 4.5); - vorapaksarjem ni priporočljiva (glejte poglavje 4.5); - fusidno kislino pri osteoartikularnih okužbah ni priporočljiva (glejte poglavje 4.5); - salmeterolom ni priporočljiva (glejte poglavje 4.5); - rivaroksabanom ni priporočljiva (glejte poglavje 4.5).
Lopinavir/ritonavir should be prescribed by physicians who are experienced in the treatment of HIV infection. 
Lopinavir/ritonavir morajo predpisovati zdravniki, ki imajo izkušnje z zdravljenjem okužbe z virusom HIV.
When Lopinavir/Ritonavir Mylan is administered concomitantly with bosentan, the efficacy of the HIV therapy should be monitored and patients should be closely observed for bosentan toxicity, especially during the first week of coadministration. 
Če je zdravilo Lopinavir/ritonavir Mylan uporabljeno sočasno z bosentanom, je treba učinkovitost zdravljenja HIV kontrolirati, bolnike pa skrbno opazovati glede toksičnosti bosentana, zlasti prvi teden sočasne uporabe.
The percentage of patients with confirmed viral rebound ≥50 copies/ml during 48 weeks of follow-up was higher in the paediatric patients receiving lopinavir/ritonavir tablets once daily (12%) than in patients receiving the twice-daily dosing (8%, p = 0.19), mainly due to lower adherence in the once-daily group. 
Odstotek bolnikov s potrjenim virusnim preobratom ≥ 50 kopij/ml v obdobju 48 tednov spremljanja je bil večji pri pediatričnih bolnikih, ki so prejemali lopinavir/ritonavir tablete enkrat na dan (12 %) kot pri bolnikih, ki so prejemali odmerek dvakrat na dan (18 %, p = 0.19), zlasti zaradi manjšega sodelovanja bolnikov v skupini, ki je prejemala odmerek enkrat na dan.
Amprenavir concentrations are significantly reduced. 
fosamprenavir: koncentracija amprenavirja se bistveno zmanjša.
If the benefit is considered to outweigh the risk and Lopinavir/Ritonavir Mylan must be used, reduce the ibrutinib dose to 140 mg and monitor patient closely for toxicity. 
Če korist odtehta tveganje in je treba zdravilo Lopinavir/ritonavir Mylan uporabiti, zmanjšajte odmerek ibrutiniba na 140 mg in pozorno spremljate bolnika za toksičnost.
Lopinavir/ritonavir has been shown in vivo to induce its own metabolism and to increase the biotransformation of some medicinal products metabolised by cytochrome P450 enzymes (including CYP2C9 and CYP2C19) and by glucuronidation. 
In vivo je bilo dokazano, da lopinavir/ritonavir inducira svojo lastno presnovo in zvečuje biotransformacijo nekaterih zdravil, ki se presnavljajo z encimi citokroma P450 (vključno s CYP2C9 in CYP2C19) in z glukuronidacijo.